PI
TPTX

Putnam Investments’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Putnam Investments’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-56,388
Closed -$2.69M – 1296
2021
Q4 		$2.69M Sell
56,388
-110,757
-66% -$4.95M ﹤0.01% 720
2021
Q3 		$11.1M Sell
167,145
-14
-0% -$997 0.02% 341
2021
Q2 		$13M Buy
167,159
+111,400
+200% +$8.23M 0.02% 319
2021
Q1 		$5.28M Buy
55,759
+1,054
+2% +$125K 0.01% 486
2020
Q4 		$6.67M Buy
+54,705
New +$5.99M 0.01% 449

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Putnam Investments's TPTX Position: Q1 2022 in Review

Putnam Investments sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 56,388 shares — an estimated $2.69M sold.

Putnam Investments first reported a position in TPTX in Q4 2020 and held it in 5 quarters. The position peaked at $13M in Q2 2021. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

  • Putnam Investments reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Putnam Investments sold 56,388 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $2.69M.
  • Putnam Investments first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Putnam Investments's Turning Point Therapeutics, Inc. Common Stock position peaked at $13M in Q2 2021.
  • 155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Putnam Investments's 13F filing for Q1 2022, filed 16 May 2022.